Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus
Strategic Profile
Athira is on track to enable dosing ALS patients in 2025. Athira continues to explore strategic alternatives focused on maximizing stockholder value after receiving topline results from its Phase 2/3 LIFT-AD clinical trial in September 2024. The company faces resource constraints and has undertaken significant cost restructuring.
Cyborg Score Rationale
Current market capitalization is $16.5M with cash, cash equivalents and investments of $25.2 million as of September 30, 2025. In 2025, the company paid a $4 million settlement relating to allegations that the CEO falsified research. The company is in survival mode exploring strategic alternatives.
Top Insights
ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers, supporting continued clinical development.
Cash position declined from $51.3M (end of 2024) to $25.2M (September 30, 2025), with Q3 2025 showing reduced quarterly burn rate.
Material legal settlement in 2025 relating to prior research falsification allegations creates execution risk.
Pivoting focus to treatment-resistant metastatic breast cancer through a new licensing program alongside ALS development.
(December 2025) Announced exclusive license to Lasofoxifene Phase 3 development program for metastatic breast cancer and financing for up to $236 million
(November 2025) Completed Phase 1 clinical study of ATH-1105 in healthy volunteers with favorable safety profile
(September 2024) Received disappointing Phase 2/3 LIFT-AD topline results for fosgonimeton in Alzheimer's disease
(2025) Paid $4 million settlement related to CEO research falsification allegations
Open the full interactive Athira Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.